The first domestic cervical cancer vaccine is priced at 329 yuan / piece and can be vaccinated in May this year

category:Society
 The first domestic cervical cancer vaccine is priced at 329 yuan / piece and can be vaccinated in May this year


The safety and preventive effect of the imported vaccine are comparable

According to the wechat account of Xiamen University, the domestic bivalent HPV vaccine on the market was jointly developed by Professor Xia Ningshao of Xiamen University and Wantai of Yangshengtang.

In terms of the safety and preventive effect of the vaccine, the domestic vaccine has the same effect as the imported vaccine.

The three phase clinical trial of vaccine was carried out in 7372 healthy women in five provinces in China. In terms of the two key effect indicators of preventing precancerous lesions and preventing HPV continuous infection, the protection rate of domestic vaccine for corresponding high precancerous lesions was 100%, and the protection rate for HPV continuous infection was 97.8%.

One shot of HPV vaccine is expected to improve

Compared with imported vaccines, domestic HPV vaccines are more affordable.

According to the wechat official account of Xiamen University, Xinkenings price is 329 yuan / piece. Women aged 9-14 only need two injections, totaling 658 yuan. Women aged 15-45 need three injections, totaling 987 yuan.

How much is the price of imported bivalent HPV vaccine? Take Beijing as an example, the price is 580 yuan / piece, and the total cost of three injections is 1740 yuan.

The approval and listing of the vaccine marks that China has begun to break the status quo of the production of HPV vaccine, which has been monopolized by foreign countries for a long time. The situation that one shot of HPV vaccine is hard to find and the gap reaches 1 billion will gradually improve. According to the wechat article of Xiamen University.

According to wechat official account of Xiamen University, it is estimated that in May this year, people will be able to get the vaccine in the community health service centers in various places.

Background

Human papillomavirus (HPV) vaccine, commonly known as cervical cancer vaccine, can be used to prevent cervical cancer in women and genital cancer and genital warts in men and women.

At present, there are three kinds of HPV vaccines on the market in the world, namely, the bivalent vaccine for HPV16 and 18 produced by GlaxoSmithKline, the bivalent vaccine for HPV6, 11, 16 and 18 produced by MSD, and the bivalent vaccine for HPV6, 11, 16, 18, 31, 33, 45, 52 and 58 produced by MSD.

According to the official website of the State Drug Administration on December 31, 2019, the bivalent human papillomavirus vaccine (e.

This is also the first domestic HPV vaccine approved for marketing in China.

(function() {(window. Slotbydup = window. Slotbydup| []). Push ({ID: u5811557, container: ssp_, async: true});}) (); source of this article: author of Beijing News: Xu Wen editor in charge: Shi Jianlei